Endotronix, Inc., a Lisle, Ill.-based digital health, medtech company dedicated to advancing the treatment of heart failure, closed a $45m Series D financing round.
The round was led by LSP, investing from its LSP Health Economics Fund 2, and included Aperture Venture Partners, BioVentures Investors, Lumira Ventures, OSF Ventures, Seroba Life Sciences, SV Health Investors, Wanxiang Healthcare Investments, and an unnamed corporate strategic investor. Endotronix will also expand the board of directors to include Fouad Azzam Ph.D., General Partner at LSP.
The company intends to use the funds for the commercialization of the Cordella™ Heart Failure System (Cordella System) and clinical development of the Cordella™ Pulmonary Artery Sensor (Cordella Sensor) through CE Marking and FDA Premarket Approval (PMA). The product platform consists of a comprehensive remote patient management software solution coupled with an integrated, next generation implantable pulmonary artery sensor to streamline heart failure care management and provide early detection of worsening heart failure.
Led by Harry Rowland, CEO, Endotronix is advancing the Cordella System, a proactive heart failure management solution that allows physicians to treat more patients with guideline-based therapy. The system extends clinical care into the home by collecting and transmitting daily patient data and insights to the heart failure clinician to guide therapy and optimal dosing.
The solution includes a cloud-based disease management data system and outpatient hemodynamic management with an implantable wireless pulmonary artery sensor for early detection of worsening heart failure.